Is There a Role for FDG PET in the Management of Lung Cancer Manifesting Predominantly as Ground-Glass Opacity?
|
|
- Meghan Lamb
- 6 years ago
- Views:
Transcription
1 Cardiopulmonary Imaging Original Research Kim et al. Role of FDG PET in Ground-Glass Opacity Lung Cancer Cardiopulmonary Imaging Original Research Tae Jung Kim 1 Chang Min Park 2 Jin Mo Goo 2 Kyung Won Lee 1 Kim TJ, Park CM, Goo JM, Lee KW Keywords: FDG PET, ground-glass opacity, lung cancer, staging DOI: /AJR Received March 15, 2011; accepted after revision May 13, Department of Radiology, Seoul National University Bundang Hospital, 166 Gumiro, Bundang-gu, Seongnam-si, Gyeonggi-do, , Republic of Korea. Address correspondence to K. W. Lee (taejung.kim1@gmail.com). 2 Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. AJR 2012; 198: X/12/ American Roentgen Ray Society Is There a Role for FDG PET in the Management of Lung Cancer Manifesting Predominantly as Ground-Glass Opacity? OBJECTIVE. The purposes of our study were to evaluate 18 F-FDG PET findings of ground-glass opacity (GGO) nodules and to determine the value of FDG PET for the preoperative staging of lung cancer manifesting predominantly as GGO. MATERIALS AND METHODS. Eighty-nine patients (46 men and 43 women; mean [± SD] age, 62.4 ± 7.2 years [range, years] and 61.7 ± 6.7 years [range, years], respectively) with 134 GGO nodules (56 single and 78 multiple) who underwent CT and FDG PET before surgery were included. CT and PET findings were assessed in terms of lesion size, GGO percentage, multiplicity, and maximum standardized uptake value (SUV max ). SUV max was correlated with lesion size and GGO percentage using linear regression. The SUV max and hypermetabolism rates of solitary and multiple GGO nodules were compared using the Student t test or Fisher exact test. Lymph node and distant organ metastasis staging by FDG PET were correlated with histopathologic findings. RESULTS. SUV max was positively correlated with lesion size (mean, 14.5 mm; range, 5 37 mm) (r = ; p < ) and was negatively correlated with GGO percentage (mean, 77%; range, %) (r = ; p < ). Solitary nodules showed higher hypermetabolism rates (73% [41/56]) than did multiple nodules (27% [21/78]) (p = ), but SUV max was not significantly different between solitary and multiple nodules. There was no true-positive interpretation of nodal or distant metastasis from GGO nodules by FDG PET. CONCLUSION. FDG PET showed no clear advantage for the staging of lung cancer with predominant GGO because of the low incidences of nodal and distant metastasis. P ET with 18F-FDG is a noninvasive diagnostic technique that provides information about glucose metabolism in lesions and is used routinely for the preoperative staging of nonsmall-cell lung cancer (NSCLC) because of its higher sensitivity and specificity than other diagnostic modalities [1, 2]. In the most widely cited metaanalysis of FDG PET in NSCLC, Gould et al. [1] found that the technique has a sensitivity of 96.8% and a specificity of 77.8% for lung cancer. However, although FDG PET is a valuable imaging modality for lung cancer staging, there are several pitfalls. It has been reported that bronchoalveolar carcinoma (BAC), which typically manifests as groundglass opacity (GGO) on CT, is falsely negative on PET [3 5]. Although numerous studies have addressed the performance characteristics of FDG PET in patients with known or suspected lung cancer, few studies have examined the accuracy of PET for BAC or adenocarcinoma with BAC components [6 8]. In addition, the clinical utility of FDG PET for the staging of lung cancer manifesting predominantly as GGO has not been thoroughly examined. The purposes of our study were to retrospectively evaluate FDG PET findings of GGO nodules and to determine the value of FDG PET for the preoperative staging of lung cancer manifesting predominantly as GGO. Materials and Methods The institutional review board of Seoul National University Bundang Hospital approved this study and waived the requirement for patient consent (IRB no. B ). Study Population Patients were identified by a retrospective data search using the terms ground-glass and GGO from the radiologic information system among the patients who underwent curative lung surgery in two tertiary hospitals (Seoul National University Bundang Hospital and Seoul National AJR:198, January
2 Kim et al. University Hospital) during January 2002 to February Patients who fulfilled the following criteria were included: pulmonary nodules with a GGO percentage of 50% or more, pulmonary nodules with pathologic confirmation by surgery, preoperative FDG PET and CT performed within 2 weeks of each other, and surgery performed within 2 weeks after PET. The percentage of GGO was calculated as follows: [(D GGO D) / D GGO ] 100, where D GGO is the greatest diameter of the lesion, including the GGO area, and D is the greatest diameter of the lesion without GGO [9, 10]. The study cohort comprised 89 patients (46 men and 43 women; mean [± SD] age, 62.4 ± 7.2 years [range, years] and 61.7 ± 6.7 years [range, years], respectively) with 134 pathologically confirmed GGO nodules. PET and CT: Imaging Protocol and Analysis PET was performed using one of two dedicated scanners (Allegro or Gemini, Philips Healthcare). All patients fasted for at least 6 hours before PET. FDG was IV injected at 5.18 MBq/kg, and whole-body scanning was performed at 50 minutes after FDG administration. The 3D row-action maximum-likelihood algorithm was used for the reconstruction of transaxial images of resolution 4.8 mm. For qualitative analysis, the degree of FDG activity in the nodules was defined as either negative (i.e., less than mediastinal blood-pool activity) or positive (i.e., same as or greater than mediastinal blood-pool activity). To analyze FDG accumulation, a circular region of interest was drawn by a board-certified nuclear medicine physician over GGO nodules on transaxial images on a slice-by-slice basis, so as to cover whole lesion A Fig year-old woman with known colon cancer. A, Axial CT image shows 1.2-cm pure ground-glass opacity nodule (arrow) in left upper lobe with negative FDG activity (maximum standardized uptake value [SUV max ] = 0.5). B, Axial CT image shows 1.5-cm solid nodule (arrow) in left lower lobe (SUV max = 1.9; data not shown). C, Coronal whole-body PET image shows hypermetabolism (arrow) (SUV max = 9.4) at colon cancer at hepatic flexure. Left upper lobe nodule was confirmed to be bronchoalveolar cell carcinoma, and left lower lobe nodule was confirmed to be pulmonary metastasis from colon cancer. volumes. In some patients, no nodules could be detected by PET because of very low FDG uptake. In these patients, regions of interest were drawn on chest CT predicted locations. Maximum standardized uptake value (SUV max ) was considered representative of FDG uptakes. FDG uptake by lymph nodes and by distant metastases and the presences of concurrent malignancies were also evaluated. When a lymph node had an SUV max of less than 2.5 g/ml or was read as no uptake, the node was considered negative. CT was performed using several CT scanners (Brilliance-64 and MX-8000 IDT, Philips Healthcare; Sensation-16 and Somatom Plus 4, Siemens Fig year-old woman with adenocarcinoma with bronchoalveolar cell carcinoma components. A, Axial CT image shows 2.8-cm mixed ground-glass opacity nodule (arrow) in right lower lobe. B, Coronal whole-body PET image shows mild hypermetabolism (arrow) (maximum standardized uptake value = 1.4). B A Healthcare; and LightSpeed Ultra and HiSpeed Advantage, GE Healthcare) with 120 kvp, ma, and a pitch of Thin-section CT images were reconstructed into 0.67 to 1.25-mm-thick sections using high-frequency algorithms. Thicksection CT images were reconstructed as 3 to 5-mmthick sections using lung reconstruction algorithms. Images were displayed with lung (level, 600 HU; width, 1500 HU) and mediastinal (level, 30 HU; width, 400 HU) window settings. One chest radiologist with 8 years of experience in chest CT interpretation, who was unaware of clinical findings and histologic diagnosis, reviewed all CT images and measured lesion size and GGO percentage. C B 84 AJR:198, January 2012
3 Role of FDG PET in Ground-Glass Opacity Lung Cancer Fig year-old woman with adenocarcinoma with bronchoalveolar cell carcinoma (BAC) components. A, Axial CT image shows 2.1-cm mixed ground-glass opacity nodule (arrow) in right upper lobe. B, Coronal whole-body PET image shows hypermetabolism at right upper lobe nodule (small arrow) (maximum standardized uptake value [SUV max ] = 2.4), right paratracheal lymph node (arrowhead) (SUV max = 4.0), and subcarinal lymph node (large arrow) (SUV max = 3.9). Right upper lobe nodule was confirmed to be adenocarcinoma with BAC components, and mediastinal lymph nodes turned out to be chronic granulomatous inflammation of tuberculosis. Pathologic Diagnoses and Postoperative Follow-Up Pathologic examinations were performed over the entire volumes of GGO nodules. Resected specimens were fixed in formalin and embedded in paraffin, and all lesion sections were stained with H and E. Hilar or mediastinal lymph node metastases were evaluated when lymph node dissection was performed. In cases with multiple primary tumors, each tumor was staged independently as a primary tumor. Lymph node metastasis or postoperative recurrence was regarded to have resulted from tumors with the most advanced stage or the largest size. Postoperative follow-up results were evaluated on the basis of clinical surveillance and CT findings. Follow-up CT was performed at 3- or 6-month intervals (BAC or adenocarcinoma with BAC components) or at 6- or 12-month intervals (atypical adenomatous hyperplasia [AAH] or focal interstitial fibrosis) in accordance with postsurgical pathologic findings. Statistical Analysis The SUV max was correlated with lesion size and GGO percentage, and the GGO percentage was correlated with lesion size with linear regression analysis. The mean SUV max and hypermetabolism rates on FDG PET were compared between nodules with different histologic profiles and between solitary and multiple GGO nodules using the unpaired Student t test or Fisher exact test, as appropriate. The GGO percentage was also compared between solitary and multiple GGO nodules using an unpaired Student t test. The proportion of AAH or BAC was compared between solitary and multiple GGO nodules using Fisher exact test; p values of less than 0.05 were considered to indicate statistical significance. Statistical analysis was performed with a statistical software package (SPSS version 15.0, SPSS). Results Demographic Findings and Histologic Diagnoses Of the 89 patients with 134 pathologically confirmed GGO nodules (mean, 1.5 nodules/ patient; range, 1 5 nodules/patient), 56 had a solitary GGO nodule and 33 had 78 multiple GGO nodules among a total of 188 GGO nodules detected by CT (mean, 2 nodules/ patient; range, 2 15 nodules/patient). The interval between PET and surgery ranged from 1 to 14 days (mean, 7 days). Pathologic specimens were obtained by lobectomy for 105 nodules, by segmentectomy for four, and by wedge resection for 25. Histologic diagnoses of the 56 solitary GGO nodules in 19 women and 37 men (mean age, 57; age range, years) included AAH (n = 3), BAC (n = 7) (Fig. 1), adenocarcinoma with BAC components (n = 45) (Figs. 2 and 3), and focal interstitial fibrosis (n = 1), and the histologic diagnoses of 78 multiple GGO nodules in 24 women and nine men (mean age, 56 years; age range, years) included AAH (n = 19), BAC (n = 26), adenocarcinoma with BAC components (n = 30), and focal interstitial fibrosis (n = 3). The proportion of AAH or BAC A in multiple GGO nodules (58% [45/78]) was significantly higher than that of solitary GGO nodules (18% [10/56]) (p = ). CT and PET Findings CT and PET results according to histologies and multiplicities of nodules are summarized in Table 1. The mean diameter of GGO nodules was 15 mm (range, 5 37 mm), and GGO nodule diameter was positively correlated with SUV max (mean, 1.2; range, ) (r = 0.67; p < ). The mean diameter of solitary GGO nodules (17 ± 8.1 mm) was significantly larger than that of multiple GGO nodules (12 ± 7.9 mm) (p < 0.001). The mean GGO percentage was 77% (range, %) and negatively correlated with SUV max (r = 0.75; p < ) and lesion size (r = 0.588; p < 0.001). Hypermetabolism rate, mean SUV max, and mean diameter of adenocarcinoma with BAC components were significantly larger than those of BAC, AAH, or focal fibrosis (p < , respectively). The mean GGO percentage of adenocarcinoma with BAC components was significantly smaller than those of BAC, AAH, or focal fibrosis (p < 0.001, respectively). The hypermetabolism rate and the mean SUV max of BAC were much larger than those of AAH (p < ). In terms of multiplicity, 41 of the 56 (73%) solitary GGO nodules showed hypermetabolism, and 21 of the 78 (27%) multiple GGO nodules showed hypermetabolism (per lesion base). The mean SUV max was 1.3 (range, ) in solitary GGO nodules and B AJR:198, January
4 Kim et al. 0.5 (range, ) in multiple GGO nodules. The hypermetabolism rate was higher for solitary than multiple GGO nodules (p = ), but the mean SUV max of solitary compared with multiple GGO nodules was not significantly different (p = ). The GGO percentage of multiple GGO nodules was significantly larger than that of solitary GGO nodules (p = ). Lung Cancer Staging: PET and Pathologic Correlations All patients with malignant nodules underwent curative resection by video-assisted thoracoscopic surgery or open thoracotomy. All malignant GGO nodules were either BAC or adenocarcinoma with BAC components; pt1n0 (n = 93) was the most common stage for both multiple and solitary GGO nodules, followed by pt2n0 (n = 15). Nodal metastases detected by both PET and pathology in two patients with a solitary GGO nodule (one pn1 and one pn2) were regarded to have resulted from concurrent solid lung cancer with a more advanced stage (pt2 adenocarcinomas) rather than from GGO nodules (pt1 BAC and pt1 adenocarcinoma, respectively). Three interpretations of mediastinal nodal metastases by PET turned out to be chronic granulomatous inflammation that was suggested by pathologic examination to be due to tuberculosis (Fig. 3); two nodes (< 10 mm in short-axis diameter) showed peripheral calcification, and one node (12 mm in short-axis diameter) showed diffuse higher attenuation (110 HU) than that in surrounding great vessels. Therefore, in the current study, there was no true-positive interpretation of nodal or distant metastasis from GGO nodules by PET. PET depicted hypermetabolism due to concurrent malignancies (n = 6) that were known at the time of PET, including concurrent solid lung cancer in three patients, pulmonary metastasis resulting from gastrointestinal malignancy in one patient, colon cancer in one patient (Fig. 1), and chondrosarcoma in the humerus in one patient. There was no recurrence over an average follow-up period of 30 months (range, months), except for one patient with adenocarcinoma (pt2n0). None of our patients died of the disease during the follow-up period. Discussion FDG PET has been shown to accurately stage NSCLC, and as a result has been widely adopted as the standard care for the evaluation of patients with NSCLC. However, the role of PET in the diagnosis and staging of BAC or adenocarcinoma with BAC components, which typically manifest as GGO at CT, has not been determined. Most studies have addressed the presence or absence of FDG uptake in terms of differentiating benign and malignant lesions [4, 11] or BAC from adenocarcinoma with BAC components [6]. Furthermore, few data are available on relationships between CT and PET findings of pulmonary GGO lesions. In the current study, SUV max showed a positive correlation with lesion size and a negative correlation with GGO percentage, both of which are known to be well correlated with histologic invasiveness and prognosis of BAC and adenocarcinoma with BAC components [12]. This concurs with the findings of Goudarzi et al. [6], who found a correlation between CT findings (i.e., size and CT density) and SUV max in BAC and adenocarcinoma with BAC components. In terms of the multiplicity of GGO nodules, we found that nodule size and hypermetabolism rate were significantly greater for solitary than multiple GGO nodules. This can be explained by the high incidence of AAH and BAC in multiple GGO nodules, because AAH and BAC are smaller and are associated with a larger proportion of GGO than those of adenocarcinoma with BAC components [10]. TABLE 1: CT and PET Results According to Histology and Multiplicity Compared with CT, PET was found to contribute little to the primary tumor staging (T staging) of lung cancer with predominant GGO; only 24% of BACs and 69% of adenocarcinomas with BAC components were FDG avid, which was similar to the results of other studies. Higashi et al. [4] reported that four of seven BACs showed negative results on PET, whereas only one of 23 non- BAC tumors showed a negative result. Port et al. [13] found that 23% of adenocarcinomas with BAC components and 58% of adenocarcinomas were FDG avid as compared with 88% of FDG-avid tumors with other histologic profiles. Although Goudarzi et al. [6] asserted that the combined findings from PET and CT could be useful for the diagnosis and management of BAC and adenocarcinoma with BAC components, preoperative differentiation of pure BAC and adenocarcinoma with BAC components cannot be accurate given that the current criteria for BAC mandate that the diagnosis be made only on examination of large (i.e., surgical) biopsy specimens [14]. In addition, although most imaging modalities used for lung cancer staging are generally not able to provide specific information on histologic subtype, lung cancer with predominant GGO at CT can strongly suggest a diagnosis of BAC or adenocarcinoma with BAC components. Therefore, the characteristic CT finding of predominant GGO has more important implications than PET results for these lesions. It is widely accepted that PET improves the detection of local and distant metastases and can prevent futile thoracotomy in patients with NSCLC [15 18]. However, it is unlikely to detect occult lymph nodes or distant metastasis in lung cancer with predominant GGO because of the low rate of metastases shown by these lesions. In the current study, no nodal or distant metastasis was found for lung cancer with predominant GGO, whereas Histologic Profile Nodule Diameter (mm) GGO Percentage PET Positivity, No. (%) of Nodules SUV max BAC (n = 33) 10 ± 6.6 (4 26) 90 ± 20 (51 100) 8 (24) 1.8 ± 1.0 ( ) Adenocarcinoma (n = 75) 20 ± 6.7 (7 36) 63 ± 19 (51 100) 52 (69) 2.9 ± 1.1 ( ) AAH (n = 22) 5 ± 2.2 (3 12) 100 ± 0 1 (5) 0.7 ± 0.5 ( ) Focal fibrosis (n = 4) 6 ± 2.0 (5 9) 89 ± 22 (56 100) 1 (25) 1.0 ± 0.9 ( ) Multiplicity Solitary GGO (n = 56) 17 ± 8.1 (5 32) 79 ± 20 (51 100) 41 (73) 1.3 ± 1.0 ( ) Multiple GGO (n = 78) 12 ± 7.9 (5 37) 92 ± 19 (51 100) 21 (27) 0.5 ± 1.1 ( ) Note Except where indicated otherwise, data are mean ± SD (range). AAH = atypical adenomatous hyperplasia, BAC = bronchoalveolar cell carcinoma, GGO = ground-glass opacity, SUV max = maximum standardized uptake value. 86 AJR:198, January 2012
5 Role of FDG PET in Ground-Glass Opacity Lung Cancer in three patients, false-positive interpretations of mediastinal nodal metastases were made by PET. According to a study on the prognostic importance of thin-section CT features in peripheral lung adenocarcinoma [12], all adenocarcinomas smaller than 2 cm with a GGO proportion exceeding 50% of tumor volume were free of lymph node metastasis and vessel invasion, and all these patients remained alive without recurrence 10 years later. After numerous initial reports proclaiming the benefits of PET in lung cancer staging, several reports have been published on the limitations of PET for the evaluation of small early lung cancer. Port et al. [13] concluded that PET has no demonstrable benefit in terms of diagnosis, staging, or prognosis in patients with a lung cancer of 2 cm or smaller because of the low prevalence of mediastinal nodal and distant metastases. In a study by Kozower et al. [19], PET prevented nontherapeutic thoracotomy in 7.4% of patients with clinical stage IA NSCLC by identifying metastatic disease, and this is significantly lower than 20% prevention rate suggested by two recent trials that both evaluated patients with potentially resectable cancer (stages IA IIIA) [16, 17]. The frequent false-positive results of PET for early lung cancer and the subsequent burden of expensive and bothersome confirmatory studies are also worrisome. False-positive results of nodal metastasis by PET occur for reactive hyperplasia or granulomatous inflammation, and thus, false-positive rates are highly dependent on the patient population [20]. In our study, all three false-positive interpretations of mediastinal nodal metastases by PET turned out to be granulomatous inflammation of tuberculosis. The standard treatment for operable NSCLC, even clinical T1N0 disease, remains lobectomy with hilar and mediastinal lymph node dissection [21]. However, clinical investigations to date have suggested that limited resection could be successfully performed for BAC that typically manifests as GGO at CT [22 24]. In addition, a recent study by Okada et al. [25] found that the nodules with GGO greater than 50% had up to 6% of nodal metastasis and up to 4% of recurrence rate and that both decreased to only 1% when the nodules had SUV max less than 1.5. In our study, FDG PET showed a higher rate of hypermetabolism in adenocarcinoma with BAC components than in BAC. These findings may suggest that a selection of sublobar resection based on a combination of information from both CT and FDG PET could be a potential clinical implication in terms of limited resection [26]. There are several limitations to this study. First, the retrospective nature of the study unavoidably introduces the issue of inherent bias. Second, SUV max analyzed in our study was subject to variability among subjects, much more than normalized SUV ratios (e.g., normalization by the liver uptake). Third, it was not feasible to evaluate the diagnostic accuracy of PET in the assessment of nodal or distant metastasis staging because no true-positive metastasis case was included. Fourth, the postoperative follow-up period was inadequate in terms of evaluating survival or disease recurrence, and longterm follow-up over several years is needed to assess prognosis accurately in lung cancer with predominant GGO. Fifth, data clustering is another possible limitation, because we included multiple nodules per patient. However, we did not adopt a statistical method, such as a generalized estimating equation approach, to manage this issue, because recent multiclonal BAC and adenocarcinoma studies have suggested that these lesions behave in an independent manner [27 29]. In summary, when CT shows a pulmonary nodule with predominant GGO, FDG PET frequently produces negative results. Furthermore, FDG PET is unlikely to detect lymph nodes or distant metastasis because of their low prevalence and, thus, does not appear to offer a clear advantage in patients with lung cancer manifesting as predominant GGO. References 1. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: Lardinois D, Weder W, Hany T, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: Cook GJR, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34: Higashi K, Ueda Y, Seki H, et al. Fluorine- 18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39: Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR 1998; 170: Goudarzi B, Jacene HA, Wahl RL. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med 2008; 49: Lee HY, Lee KS, Han J, et al. Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer 2009; 65: Okada M, Tauchi S, Iwanaga K, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. J Thorac Cardiovasc Surg 2007; 133: Kim TJ, Lee J-H, Lee C-T, et al. Diagnostic accuracy of CT-guided core biopsy of ground-glass opacity pulmonary lesions. AJR 2008; 190: Kim TJ, Goo JM, Lee KW, Park CM, Lee HJ. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer 2009; 64: Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38: Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001; 220: Port JL, Andrade RS, Levin MA, et al. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg 2005; 130: Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization Pathologic Criteria. J Thorac Oncol 2006; 1:S13 S Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS mul- AJR:198, January
6 Kim et al. ticentre randomised trial. Lancet 2002; 359: Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004; 22: Kozower BD, Meyers BF, Reed CE, Jones DR, Decker PA, Putnam JB Jr. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg 2008; 85: Shim SS, Lee KS, Kim B-T, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005; 236: Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: Arenberg D. Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines 2nd edition. Chest 2007; 132:306S 313S 23. Kodama K, Higashiyama M, Takami K, et al. Treatment strategy for patients with small peripheral lung lesion(s): intermediate-term results of prospective study. Eur J Cardiothorac Surg 2008; 34: Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg 2003; 125: Okada M, Nakayama H, Okumura S, et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/ computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg 2011; 141: Yoshioka M, Ichiguchi O. Selection of sublobar resection for c-stage IA non-small cell lung cancer based on a combination of structural imaging by CT and functional imaging by FDG PET. Ann Thorac Cardiovasc Surg 2009; 15: Nanki N, Fujita J, Hojo S, et al. Evaluation of the clonality of multilobar bronchioloalveolar carcinoma of the lung: case report. Am J Clin Oncol 2002; 25: Barsky SH, Grossman DA, Ho J, Holmes EC. The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Mod Pathol 1994; 7: Okubo K, Mark EJ, Flieder D, et al. Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. J Thorac Cardiovasc Surg 1999; 118: FOR YOUR INFORMATION The comprehensive book based on the ARRS 2011 annual meeting categorical course on Imaging of the Active Lifestyle: From the Weekend Warrior to the Pro Athlete is now available! For more information or to purchase a copy, see 88 AJR:198, January 2012
Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma
ORIGINAL ARTICLE Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Jhingook Kim, MD, PhD,* Young Mog Shim, MD,
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationWith recent advances in diagnostic imaging technologies,
ORIGINAL ARTICLE Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Kwhanmien Kim, MD,* Young Mog
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationDoes Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer?
Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer? Benjamin D. Kozower, MD, Bryan F. Meyers, MD, Carolyn E. Reed, MD, David R. Jones, MD, Paul
More informationI appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
More informationRisk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationUniportal video-assisted thoracoscopic surgery segmentectomy
Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;
More informationThoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis
19 th Congress of APSR PG of Lung Cancer (ESAP): Update of Lung Cancer Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis Kazuma Kishi, M.D. Department of Respiratory Medicine,
More informationNoninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index
doi: 10.5761/atcs.oa.14-00241 Original Article Noninvasive Differential Diagnosis of Pulmonary Nodules Using the Standardized Uptake Value Index Satoshi Shiono, MD, 1 Naoki Yanagawa, MD, 2 Masami Abiko,
More informationDiffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy
Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy Poster No.: C-1785 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific
More informationSolid part size is an important predictor of nodal metastasis in lung cancer with a subsolid tumor
Cho et al. BMC Pulmonary Medicine (2018) 18:151 https://doi.org/10.1186/s12890-018-0709-2 RESEARCH ARTICLE Solid part size is an important predictor of nodal metastasis in lung cancer with a subsolid tumor
More informationImaging Decisions Start Here SM
Owing to its high resolution and wide anatomic coverage, dynamic first-pass perfusion 320-detector-row CT outperforms PET/CT for distinguishing benign from malignant lung nodules, researchers from Japan
More informationGTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 3 607
Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationThe Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
More informationOriginal Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study
Int J Clin Exp Med 2016;9(5):8765-8769 www.ijcem.com /ISSN:1940-5901/IJCEM0017315 Original Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study Zhijun Zhu,
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationWhack-a-mole strategy for multifocal ground glass opacities of the lung
Review Article Whack-a-mole strategy for multifocal ground glass opacities of the lung Kenji Suzuki General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan Correspondence to: Kenji
More informationPathology and Prognosis of Persistent Stable Pure Ground-Glass Opacity Nodules After Surgical Resection
GENERAL THORACIC Pathology and Prognosis of Persistent Stable Pure Ground-Glass Opacity Nodules After Surgical Resection Sukki Cho, MD, HeeChul Yang, MD, Kwhanmien Kim, MD, and Sanghoon Jheon, MD Department
More informationAnthony J. Paravati 1, David W. Johnstone 2, Marc A. Seltzer 3, Candice A. Johnstone 4. Introduction
Original Article Negative predictive value (NPV) of FDG PET-CT for nodal disease in clinically node-negative early stage lung cancer (AJCC 7 th ed T1-2aN0) and identification of risk factors for occult
More informationInvasive Pulmonary Adenocarcinomas versus Preinvasive Lesions Appearing as Ground-Glass Nodules: Differentiation by Using CT Features 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Sang Min Lee, MD
More informationResults of Wedge Resection for Focal Bronchioloalveolar Carcinoma Showing Pure Ground-Glass Attenuation on Computed Tomography
Results of Wedge Resection for Focal Bronchioloalveolar Carcinoma Showing Pure Ground-Glass Attenuation on Computed Tomography Shun-ichi Watanabe, MD, Toshio Watanabe, MD, Kazunori Arai, MD, Takahiko Kasai,
More informationXiaohuan Pan 1,2 *, Xinguan Yang 1,2 *, Jingxu Li 1,2, Xiao Dong 1,2, Jianxing He 2,3, Yubao Guan 1,2. Original Article
Original Article Is a 5-mm diameter an appropriate cut-off value for the diagnosis of atypical adenomatous hyperplasia and adenocarcinoma in situ on chest computed tomography and pathological examination?
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationNodular Ground-Glass Opacities on Thin-section CT: Size Change during Follow-up and Pathological Results
Nodular Ground-Glass Opacities on Thin-section CT: Size Change during Follow-up and Pathological Results Hyun Ju Lee, MD 1 Jin Mo Goo, MD 1 Chang Hyun Lee, MD 1 Chul-Gyu Yoo, MD 2 Young Tae Kim, MD 3 Jung-Gi
More informationLow-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules Management Version 2
Low-dose CT Lung Cancer Screening Guidelines for Pulmonary Nodules Management Version 2 The Committee for Management of CT-screening-detected Pulmonary Nodules 2009-2011 The Japanese Society of CT Screening
More informationNovel Asymmetrical Linear Stapler (NALS) for pathologic evaluation of true resection margin tissue
Original Article Novel Asymmetrical Linear Stapler (NALS) for pathologic evaluation of true resection margin tissue Shin-Kwang Kang #, Jin San Bok #, Hyun Jin Cho, Min-Woong Kang Department of Thoracic
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationSublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer
Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,
More informationPulmonary Nodules & Masses
Pulmonary Nodules & Masses A Diagnostic Approach Heber MacMahon The University of Chicago Department of Radiology Disclosure Information Consultant for Riverain Technology Minor equity in Hologic Royalties
More informationPULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES. https://tinyurl.com/hmpn2018
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES Heber MacMahon MB, BCh Department of Radiology The University of Chicago https://tinyurl.com/hmpn2018 Disclosures Consultant
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationOmission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures
Review Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures Hiroaki Nomori, MD, PhD, Kazunori Iwatani, MD, Hironori Kobayashi, MD, Atsushi Mori, MD, and
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationLUNG NODULES: MODERN MANAGEMENT STRATEGIES
Department of Radiology LUNG NODULES: MODERN MANAGEMENT STRATEGIES Christian J. Herold M.D. Department of Biomedical Imaging and Image-guided Therapy Medical University of Vienna Vienna, Austria Pulmonary
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationGUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES
Venice 2017 GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES Heber MacMahon MB, BCh Department of Radiology The University of Chicago Disclosures Consultant for Riverain Medical
More informationS taging non-small lung cancer (NSCLC) is an important
696 LUNG CANCER Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study K G Tournoy, S Maddens, R Gosselin, G
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationPrognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule
Original Article Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Jong Hui Suh 1, Jae Kil Park 2, Youngkyu Moon 2 1 Department of Thoracic & Cardiovascular Surgery,
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationHistory of Limited Resection for Non-small Cell Lung Cancer
Review History of Limited Resection for n-small Cell Lung Cancer Haruhiko Nakamura, MD, PhD, 1 Sugishita Kazuyuki, MD, 1 rihito Kawasaki, MD, 1 Masahiko Taguchi, MD, PhD, 1 and Harubumi Kato, MD, PhD 2
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationBronchioloalveolar carcinoma (BAC) is an imprecise term
Original Article Outcomes of Unresected Ground-Glass Nodules with Cytology Suspicious for Adenocarcinoma Caroline M. Gulati, MD,* Andrew M. Schreiner, MD, Daniel M. Libby, MD,* Jeffrey L. Port, MD, Nasser
More informationSynchronous Triple Primary Lung Cancers: A Case Report
Case Report Thoracic Imaging http://dx.doi.org/10.3348/kjr.2014.15.5.646 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(5):646-650 Synchronous Triple Primary Lung Cancers: A Case Report Hyun Jung
More informationSince the randomized phase III trial conducted by the Lung
ORIGINAL ARTICLE Reasonable Extent of Lymph Node Dissection in Intentional Segmentectomy for Small-Sized Peripheral Non Small-Cell Lung Cancer From the Clinicopathological Findings of Patients Who Underwent
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationThe long-term course of ground-glass opacities detected on thin-section computed tomography
Respiratory Medicine (2013) 107, 904e910 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed The long-term course of ground-glass opacities detected on thin-section
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationThe 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
More informationHRCT features distinguishing minimally invasive adenocarcinomas from invasive adenocarcinomas appearing as mixed ground-glass nodules
Original Article HRCT features distinguishing minimally invasive adenocarcinomas from invasive adenocarcinomas appearing as mixed ground-glass nodules Wei Yu 1, Zhaoyu Wang 2, Liyong Qian 2, Shanjun Wang
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationNatural History of Pure Ground-Glass Opacity After Long-Term Follow-up of More Than 2 Years
Natural History of Pure Ground-Glass Opacity After Long-Term Follow-up of More Than 2 Years Ken Kodama, MD, Masahiko Higashiyama, MD, Hideoki Yokouchi, MD, Koji Takami, MD, Keiko Kuriyama, MD, Yoko Kusunoki,
More informationSince the introduction of low-dose helical computed tomography
Original Article Prognostic Impact of Tumor Size Eliminating the Ground Glass Opacity Component Modified Clinical T Descriptors of the Tumor, Node, Metastasis Classification of Lung Cancer Shota Nakamura,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe small subsolid pulmonary nodules. What radiologists need to know.
The small subsolid pulmonary nodules. What radiologists need to know. Poster No.: C-1250 Congress: ECR 2016 Type: Educational Exhibit Authors: L. Fernandez Rodriguez, A. Martín Díaz, A. Linares Beltrán,
More informationThe IASLC/ATS/ERS classification of lung adenocarcinoma-a surgical point of view
Review Article The IASLC/ATS/ERS classification of lung adenocarcinoma-a surgical point of view Wentao Fang 1, Yangwei Xiang 1, Chenxi Zhong 1, Qunhui Chen 2 1 Department of Thoracic Surgery, 2 Department
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationUnusual False-Positive Mesenteric Lymph Nodes Detected by PET/CT in a Metastatic Survey of Lung Cancer
DOI: 10.1159/000446579 Published online: June 14, 2016 2016 The Author(s) Published by S. Karger AG, Basel This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationImaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography
GENERAL THORACIC 11 C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography Hiroaki Nomori, MD, PhD, Noboru Kosaka,
More informationHow Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?
Original Article How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed? Yoshihisa Kobayashi, MD,* Takayuki Fukui, MD,* Simon Ito, MD,* Noriyasu Usami, MD,* Shunzo Hatooka, MD,* Yasushi
More informationOncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer
Oncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationGuidelines for the Management of Pulmonary Nodules Detected by Low-dose CT Lung Cancer Screening
Guidelines for the Management of Pulmonary Nodules Detected by Low-dose CT Lung Cancer Screening 1. Introduction In January 2005, the Committee for Preparation of Clinical Practice Guidelines for the Management
More informationStage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis
Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting
More informationResearch Article The Advantage of PET and CT Integration in Examination of Lung Tumors
Hindawi Publishing Corporation International Journal of Biomedical Imaging Volume 2007, Article ID 17131, 5 pages doi:10.1155/2007/17131 Research Article The Advantage of PET and CT Integration in Examination
More informationApproach to Pulmonary Nodules
Approach to Pulmonary Nodules Edwin Jackson, Jr., DO Assistant Professor-Clinical Director, James Early Detection Clinic Department of Internal Medicine Division of Pulmonary, Allergy, Critical Care and
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationFactors that predict lymph node status in clinical stage T1aN0M0 lung adenocarcinomas
Ye et al. World Journal of Surgical Oncology 2014, 12:42 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Factors that predict lymph node status in clinical stage T1aN0M0 lung adenocarcinomas Bo
More informationOncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer
Oncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationRadiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
More informationLung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture
Cronicon OPEN ACCESS EC PULMONOLOGY AND RESPIRATORY MEDICINE Case Report Lung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture Swan Lee 1 and Rolando Sanchez Sanchez
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationThoracoscopic wedge resection and segmentectomy for smallsized pulmonary nodules
Perspective on Thoracic Surgery Thoracoscopic wedge resection and segmentectomy for smallsized pulmonary nodules Hirohisa Kato, Hiroyuki Oizumi, Jun Suzuki, Akira Hamada, Hikaru Watarai, Kenta Nakahashi,
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationNavigational bronchoscopy-guided dye marking to assist resection of a small lung nodule
Case Report on Aerodigestive Endoscopy Navigational bronchoscopy-guided dye marking to assist resection of a small lung nodule Jennifer L. Sullivan 1, Michael G. Martin 2, Benny Weksler 1 1 Division of
More informationCase Report PET/CT Imaging in Oncology: Exceptions That Prove the Rule
Case Reports in Oncological Medicine Volume 2013, Article ID 865032, 4 pages http://dx.doi.org/10.1155/2013/865032 Case Report PET/CT Imaging in Oncology: Exceptions That Prove the Rule M. Casali, 1 A.
More informationLung Cancer Diagnosis for Primary Care
Lung Cancer Diagnosis for Primary Care Daniel Nader, DO, FCCP Cancer Treatment Center of America Case 1 In which of the following situations would the U.S. Preventive Services Task Force (USPSTF) recommend
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationThe revised lung adenocarcinoma classification an imaging guide
Review Article The revised lung adenocarcinoma classification an imaging guide Natasha Gardiner 1, Sanjay Jogai 2, Adam Wallis 3 1 Specialty Registrar in Clinical Radiology, Wessex Deanery, UK; 2 Consultant
More informationCharacteristics of Subsolid Pulmonary Nodules Showing Growth During Follow-up With CT Scanning
CHEST Original Research Characteristics of Subsolid Pulmonary Nodules Showing Growth During Follow-up With CT Scanning Haruhisa Matsuguma, MD ; Kiyoshi Mori, MD ; Rie Nakahara, MD ; Haruko Suzuki, MD ;
More information